Impact of fibre and red/processed meat intake on treatment outcomes among patients with chronic inflammatory diseases initiating biological therapy: A prospective cohort study.
biologic therapy
chronic inflammatory disease
diet
fibre
inflammatory bowel disease
processed meat
red meat
rheumatoid arthritis
Journal
Frontiers in nutrition
ISSN: 2296-861X
Titre abrégé: Front Nutr
Pays: Switzerland
ID NLM: 101642264
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
07
2022
accepted:
20
09
2022
entrez:
31
10
2022
pubmed:
1
11
2022
medline:
1
11
2022
Statut:
epublish
Résumé
Biologic disease-modifying drugs have revolutionised the treatment of a number of chronic inflammatory diseases (CID). However, up to 60% of the patients do not have a sufficient response to treatment and there is a need for optimization of treatment strategies. To investigate if the treatment outcome of biological therapy is associated with the habitual dietary intake of fibre and red/processed meat in patients with a CID. In this multicentre prospective cohort study, we consecutively enrolled 233 adult patients with a diagnosis of Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis (RA), Axial Spondyloarthritis, Psoriatic Arthritis and Psoriasis, for whom biologic therapy was planned, over a 3 year period. Patients with completed baseline food frequency questionnaires were stratified into a high fibre/low red and processed meat exposed group (HFLM) and an unexposed group (low fibre/high red and processed meat intake = LFHM). The primary outcome was the proportion of patients with a clinical response to biologic therapy after 14-16 weeks of treatment. Of the 193 patients included in our primary analysis, 114 (59%) had a clinical response to biologic therapy. In the HFLM group ( Habitual HFLM intake did not affect the clinical response to biological treatment across CIDs. HFLM diet in RA patients might be associated with better odds for responding to biological treatment, but this would need confirmation in a randomised trial. (clinicaltrials.gov), identifier [NCT03173144].
Sections du résumé
Background
UNASSIGNED
Biologic disease-modifying drugs have revolutionised the treatment of a number of chronic inflammatory diseases (CID). However, up to 60% of the patients do not have a sufficient response to treatment and there is a need for optimization of treatment strategies.
Objective
UNASSIGNED
To investigate if the treatment outcome of biological therapy is associated with the habitual dietary intake of fibre and red/processed meat in patients with a CID.
Methods
UNASSIGNED
In this multicentre prospective cohort study, we consecutively enrolled 233 adult patients with a diagnosis of Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis (RA), Axial Spondyloarthritis, Psoriatic Arthritis and Psoriasis, for whom biologic therapy was planned, over a 3 year period. Patients with completed baseline food frequency questionnaires were stratified into a high fibre/low red and processed meat exposed group (HFLM) and an unexposed group (low fibre/high red and processed meat intake = LFHM). The primary outcome was the proportion of patients with a clinical response to biologic therapy after 14-16 weeks of treatment.
Results
UNASSIGNED
Of the 193 patients included in our primary analysis, 114 (59%) had a clinical response to biologic therapy. In the HFLM group (
Conclusion
UNASSIGNED
Habitual HFLM intake did not affect the clinical response to biological treatment across CIDs. HFLM diet in RA patients might be associated with better odds for responding to biological treatment, but this would need confirmation in a randomised trial.
Trial registration
UNASSIGNED
(clinicaltrials.gov), identifier [NCT03173144].
Identifiants
pubmed: 36313095
doi: 10.3389/fnut.2022.985732
pmc: PMC9609158
doi:
Banques de données
ClinicalTrials.gov
['NCT03173144']
Types de publication
Journal Article
Langues
eng
Pagination
985732Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2022 Overgaard, Sørensen, Munk, Nexøe, Glerup, Henriksen, Guldmann, Pedersen, Saboori, Hvid, Dahlerup, Hvas, Jawhara, Andersen, Pedersen, Nielsen, Bergenheim, Brodersen, Heitmann, Halldorsson, Holmskov, Bygum, Christensen, Kjeldsen, Ellingsen and Andersen.
Déclaration de conflit d'intérêts
Author CH has received speaker fee from Takeda Pharma and Tillotts Pharma (unrelated to the present work). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biochim Biophys Acta Mol Cell Biol Lipids. 2021 May;1866(5):158900
pubmed: 33571672
BMJ. 2008 Sep 11;337:a1344
pubmed: 18786971
Aliment Pharmacol Ther. 2016 Jan;43(2):181-96
pubmed: 26527169
Rheum Dis Clin North Am. 2015 Nov;41(4):545-68
pubmed: 26476218
N Engl J Med. 2017 Mar 9;376(10):957-970
pubmed: 28273019
Int J Surg. 2014 Dec;12(12):1500-24
pubmed: 25046751
PLoS Med. 2006 Aug;3(8):e297
pubmed: 16942393
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Front Med (Lausanne). 2018 Dec 14;5:349
pubmed: 30619860
Arthritis Res Ther. 2006;8(1):R29
pubmed: 16507128
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Ann Rheum Dis. 2009 Jun;68 Suppl 2:ii1-44
pubmed: 19433414
BMJ. 2020 May 28;369:m1590
pubmed: 32467098
Pathogens. 2020 Jun 12;9(6):
pubmed: 32545459
Nat Rev Rheumatol. 2021 Oct;17(10):585-595
pubmed: 34341562
Arthritis Rheum. 1995 Jun;38(6):727-35
pubmed: 7779114
Gut. 2021 Jul;70(7):1287-1298
pubmed: 33811041
Stat Med. 2009 Nov 10;28(25):3083-107
pubmed: 19757444
Inflamm Bowel Dis. 2018 Mar 19;24(4):742-751
pubmed: 29562277
Nat Rev Gastroenterol Hepatol. 2020 Feb;17(2):76-77
pubmed: 31848474
Nutrients. 2021 Feb 22;13(2):
pubmed: 33671569
Med Sci Monit. 2012 Aug;18(8):PI17-20
pubmed: 22847212
Ann Rheum Dis. 2014 Jul;73(7):1316-22
pubmed: 24550173
Front Pharmacol. 2017 Jul 12;8:460
pubmed: 28785220
JAMA. 2014 Aug 6;312(5):543-4
pubmed: 25096694
Nutr Res Rev. 2020 Dec;33(2):181-189
pubmed: 31918784
Therap Adv Gastroenterol. 2015 Jul;8(4):168-75
pubmed: 26136834
Ann Intern Med. 2007 Oct 16;147(8):W163-94
pubmed: 17938389
BMJ. 2003 Jan 25;326(7382):219
pubmed: 12543843
Int J Mol Sci. 2020 Jul 29;21(15):
pubmed: 32751360
Lancet. 2017 Jul 1;390(10089):73-84
pubmed: 28110981
Curr Opin Immunol. 2017 Dec;49:1-8
pubmed: 28738209
Pharmacol Res. 2020 Sep;159:104947
pubmed: 32492488
J Clin Epidemiol. 2021 Jun;134:174-177
pubmed: 34016442
BMJ Open. 2018 Feb 8;8(2):e018166
pubmed: 29439003
J Crohns Colitis. 2021 Dec 18;15(12):2041-2053
pubmed: 34216206
Nat Rev Rheumatol. 2021 Apr;17(4):224-237
pubmed: 33674813
Autoimmun Rev. 2018 Nov;17(11):1115-1123
pubmed: 30213700
Ann Gastroenterol. 2018 Jul-Aug;31(4):469-473
pubmed: 29991892
Cell. 2016 Nov 17;167(5):1339-1353.e21
pubmed: 27863247
JAMA. 2018 Oct 02;320(13):1360-1372
pubmed: 30285183
Nat Rev Gastroenterol Hepatol. 2020 Jan;17(1):9-20
pubmed: 31767987
Lancet. 2019 Feb 2;393(10170):447-492
pubmed: 30660336
RMD Open. 2019 Apr 24;5(1):e000880
pubmed: 31168408
Nutr Res Rev. 2017 Dec;30(2):149-190
pubmed: 28676135
Scand J Public Health. 2011 Mar;39(2):203-11
pubmed: 21257645
Public Health Nutr. 2015 Aug;18(11):1914-21
pubmed: 25382388
N Engl J Med. 2013 Aug 22;369(8):754-62
pubmed: 23964937
Autoimmun Rev. 2005 Mar;4(3):130-6
pubmed: 15823498
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9
pubmed: 15083780
Perm J. 2015 Winter;19(1):58-61
pubmed: 25663207